Jefferies initiates Amer Sports stock with buy on brand growth

Jefferies initiated coverage of Amer Sports with a Buy rating and a $42 price target, versus a $28.37 share price cited in the article. It forecasts Salomon sales exceeding $2.5 billion in 2026 and reaching $3 billion before 2028, and expects Amer Sports EPS to grow 22% in 2027. Other analysts also cited growth potential, though Morgan Stanley resumed coverage at Equalweight, saying the growth and profitability profile was largely reflected in expectations.

Analysis

The key underwriting question is whether Amer Sports can add a second durable growth engine without diluting the premium economics investors are underwriting. Salomon’s expansion broadens the growth base and could reduce dependence on Arc’teryx; it also raises the risk that Sportstyle demand is more trend-sensitive and less durable than technical footwear demand. New-to-brand customers are encouraging, but repeat purchase, full-price sell-through and inventory turns matter more than web traffic or early product adoption.

The bullish analyst cluster is a positioning risk, not independent confirmation: if expectations are already elevated, merely meeting growth plans may not support further multiple expansion. Morgan Stanley’s equalweight stance is a useful counterweight. The West-versus-China shift could diversify regional exposure, but it does not eliminate execution risk in distribution, marketing spend or demand; investment required to sustain growth could pressure operating leverage before revenue catches up.

Near term (days to weeks), the initiation itself is unlikely to be a durable catalyst after multiple positive ratings. Over 1–3 months, monitor reported regional growth, Salomon sell-through, inventory and gross-margin direction. Over 6–18 months, the thesis depends on Salomon scaling while Arc’teryx retains pricing power. The thesis weakens if growth relies on discounting, inventories outpace sales, or margin guidance deteriorates. Competitors such as On Holding, Deckers and Nike may face incremental competition for premium footwear demand, but the article provides no evidence of share loss.

Key Decisions for Investors

• AS: Consider a staged, modest long rather than chasing analyst-driven strength; add only if reported sell-through and revenue growth validate demand without inventory or margin deterioration. Upside is continued earnings delivery and a broader growth mix; downside is multiple compression if optimistic expectations meet merely average execution.
• Before sizing, verify the current share price and valuation, the basis for the cited 2026 growth estimates, and the latest inventory, full-price sell-through and regional revenue disclosures. Analyst targets and web visits are not substitutes for realized sales and cash conversion.
• Use earnings disclosures over the next 1–3 months as the principal catalyst check. Reduce or exit the thesis if inventory grows faster than sales, management signals material discounting, or gross-margin/operating-margin outlook weakens; sustained growth with stable margins would argue for holding through the longer-term brand expansion.